Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma.

Zhou, Shi-Qiong; Wan, Peng; Zhang, Sen; Ren, Yuan; Li, Hong-Tao; Ke, Qing-Hua

Zhou, Shi-Qiong; Wan, Peng; Zhang, Sen; Ren, Yuan; Li, Hong-Tao; Ke, Qing-Hua.

Afiliação

Zhou SQ; Department of Chemoradiotherapy, The First Affiliated Hospital of Yangtze University, Jingzhou 434000, Hubei Province, China.
Wan P; Department of Chemoradiotherapy, The First Affiliated Hospital of Yangtze University, Jingzhou 434000, Hubei Province, China.
Zhang S; Department of Chemoradiotherapy, The First Affiliated Hospital of Yangtze University, Jingzhou 434000, Hubei Province, China.
Ren Y; Department of Chemoradiotherapy, The First Affiliated Hospital of Yangtze University, Jingzhou 434000, Hubei Province, China.
Li HT; Department of Chemoradiotherapy, The First Affiliated Hospital of Yangtze University, Jingzhou 434000, Hubei Province, China.
Ke QH; Department of Chemoradiotherapy, The First Affiliated Hospital of Yangtze University, Jingzhou 434000, Hubei Province, China. 3803354759@qq.com.

World J Clin Oncol ; 15(7): 859-866, 2024 Jul 24.

Article em En | MEDLINE | ID: mdl-39071470

Palavras-chave

Concurrent chemoradiotherapy; Immunotherapy; Locally advanced pancreatic adenocarcinoma; Programmed cell death 1; Sintilimab

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: World J Clin Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google